Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Patient and Healthcare Professional Preferences for Characteristics of Long-Acting Injectable Antipsychotic Agents for the Treatment of Schizophrenia ; volume:40 ; number:5 ; day:11 ; month:3 ; year:2023 ; pages:2249-2264 ; date:5.2023
Advances in therapy ; 40, Heft 5 (11.3.2023), 2249-2264, 5.2023
- Urheber
-
Robinson, Delbert G.
Suett, Mark
Wilhelm, Amanda
Chaijale, Nayla
Franzenburg, Kelli R.
Gandhi, Sanjay
Cloud, Blaine
Mychaskiw, Marko
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-023-02455-8
- URN
-
urn:nbn:de:101:1-2023090410024524906331
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Robinson, Delbert G.
- Suett, Mark
- Wilhelm, Amanda
- Chaijale, Nayla
- Franzenburg, Kelli R.
- Gandhi, Sanjay
- Cloud, Blaine
- Mychaskiw, Marko
- SpringerLink (Online service)
Ähnliche Objekte (12)
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders
Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders
Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs
Long-acting injectable atovaquone nanomedicines for malaria prophylaxis
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
Three-year clinical experience with the long-acting injectable formulation of the atypical antipsychotic risperidone
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study
Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
Healthcare resource utilization and costs before and after long-acting injectable antipsychotic initiation in commercially insured young adults with schizophrenia
Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders
Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness
Attitudes of European physicians towards the use of long-acting injectable antipsychotics